Trial Profile

The effects of metabolic parameters of aripiprazole in patients with schizophrenia.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aripiprazole (Primary)
Indications Schizophrenia
Focus Therapeutic Use

Most Recent Events

17 Jun 2009 Planned end date changed from 1 Sep 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
14 Jul 2008 Status changed from in progress to recruiting as reported by ClinicalTrials.gov.
28 Dec 2007 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com